logo
Reality check: Does apple cider vinegar have health benefits?

Reality check: Does apple cider vinegar have health benefits?

Globe and Mail19-05-2025

For centuries, apple cider vinegar has been used to treat a range of ills such as fever, coughs and colds.
Today, social media influencers and celebrities praise the tart, sour-tasting liquid for its ability to detox the body, lower blood sugar and cholesterol, banish bloating, burn body fat, get rid of acne and more.
Sounds too good to be true?
There is reason to be skeptical about many of apple cider vinegar's health claims.
For one or two, though, the evidence, while not robust, suggests it may be helpful. Here's what to know.
Apple cider vinegar (ACV) is made by fermenting crushed apples with yeast, which turn the sugars into alcohol.
A second fermentation then allows bacteria to convert the alcohol into acetic acid, the compound that gives vinegar its characteristic sour taste and smell.
Pasteurized apple cider vinegar is heat-treated to kill bacteria and extend shelf life. Unpasteurized apple cider vinegar is cloudy and contains the 'mother', a sediment of gut-healthy microbes.
Apple cider vinegar is available as a liquid, and also as tablet and gummy supplements; studies have focused on the liquid form.
Here's where the evidence stands on ACV's purported health and wellness benefits.
A 2025 review of clinical trials involving 463 adults with type 2 diabetes concluded that taking one to two tablespoons of ACV daily for at least eight weeks significantly reduced fasting blood glucose and hemoglobin A1c compared to placebo. (A hemoglobin A1c test measures your average blood sugar level over the previous three months.)
Two earlier meta-analyses of mostly low-quality clinical trials conducted in adults with overweight, obesity and/or Type 2 diabetes found that taking ACV daily for up to 12 weeks improved fasting glucose, hemoglobin A1c, total cholesterol and blood triglycerides. However, these beneficial effects were limited to participants with Type 2 diabetes.
There was no effect of ACV on LDL (bad) cholesterol levels in the bloodstream.
A clinical study from Iran involving 80 adults with Type 2 diabetes did find that, compared to the placebo treatment, taking two tablespoons of ACV daily for eight weeks significantly lowered LDL cholesterol.
Bottom line: ACV may lower blood glucose in people with Type 2 diabetes. It's unclear, though, whether it's beneficial for high blood cholesterol.
Acetic acid in ACV is thought to slow the rate that food empties from the stomach into the small intestine, causing a slower release and rise of glucose into the bloodstream. Acetic acid may also increase the body's ability to metabolize glucose and fats.
Studies investigating the impact of ACV on weight loss are few, small in size and of short duration.
A 2018 study found that taking one tablespoon of ACV twice daily for 12 weeks, while eating a calorie-restricted diet, reduced appetite and resulted in a modest weight loss compared to dieting alone.
It was unclear, though, whether eating fewer calories or taking apple cider vinegar influenced the findings.
A 2024 clinical study from Lebanon involving 120 participants, ages 12 to 25, who were overweight or living with obesity found that consuming one, two or three teaspoons of ACV daily for 12 weeks resulted in a significant reduction in body weight compared to placebo.
Measures of fasting blood glucose, cholesterol and triglycerides also improved in the ACV group.
Participants kept food diaries, but calorie and nutrient intakes weren't analyzed by the researchers. It's not known if participants changed the quantity or types of foods they ate during the study.
Consuming acetic acid with a meal may increase satiety, possibly helping you consume fewer calories during the day. Even so, ACV is not a magic bullet for weight loss.
There's no scientific evidence that ACV improves bloating, indigestion or acid reflux.
It's possible that consuming unpasteurized ACV, a natural source of probiotics, can benefit gut health by increasing the diversity and richness of the gut microbiome.
When it comes to clearing up acne, there's not enough reliable evidence to assess ACV's effectiveness. Ditto for using it topically to treat eczema or remove warts.
ACV is considered safe when consumed in food amounts.
It may, though, interact with some medications for diabetes and congestive heart failure, as well as certain diuretics. Consult your doctor before using ACV.
Don't drink ACV straight. Its high acidity can irritate your throat and esophagus, worsen acid reflux and damage tooth enamel.
Dilute one tablespoon of vinegar in eight ounces of water. Drink it before a meal once or twice a day. Or consume it as part of a meal in a vinaigrette salad dressing.
Acetic acid isn't unique to ACV. All vinegars contain it; balsamic, red wine, white wine and distilled white vinegar can be a substitute for apple cider vinegar.
Leslie Beck, a Toronto-based private practice dietitian, is director of food and nutrition at Medcan. Follow her on X @LeslieBeckRD

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

Globe and Mail

timean hour ago

  • Globe and Mail

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

– ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma – – BioRestorative to release new clinical data to the public prior to market open on June 13th – MELVILLE, N.Y., June 09, 2025 — BioRestorative Therapies, Inc. ('BioRestorative,' 'BRTX' or the 'Company') (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong. The highly anticipated presentation will be delivered by Francisco Silva, Vice President of Research and Development at BioRestorative, on Friday, June 13, at 5:00 p.m. HKT, as part of ISSCR 2025's clinical innovations track. The Company will issue a press release pre-market that day, detailing the newly reported data. 'This represents a milestone moment for BioRestorative,' said Lance Alstodt, Chief Executive Officer. 'With preliminary data from twice as many patients as previously shared, we are seeing strong, consistent signals around both safety and functional improvement. We are eager to bring this update to the global scientific community at the world's most influential stem cell conference.' BRTX-100 is BioRestorative's lead clinical candidate — a hypoxic-cultured, autologous mesenchymal stem cell therapy designed to target areas of the body with limited blood flow, such as damaged spinal discs. The ongoing Phase 2 study is a prospective, randomized, double-blinded, placebo-controlled trial evaluating BRTX-100 in patients with cLDD across up to 16 U.S. clinical sites. A total of 99 patients will be enrolled, randomized 2:1 to receive either BRTX-100 or placebo via a single intradiscal injection. The presentation, titled 'Stem Cell Therapy for Chronic Lumbar Disc Disease: Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells,' will highlight key preliminary outcomes focused on patient-reported pain and function metrics, as well as safety endpoints. About the ISSCR 2025 Annual Meeting ISSCR 2025 is the largest and most influential gathering of stem cell scientists and regenerative medicine experts globally, attracting nearly 4,000 participants from over 80 countries. It serves as a key venue for groundbreaking clinical and translational research, offering BioRestorative a high-profile platform to share its latest advancements. For more information on ISSCR 2025, visit About BioRestorative Therapies, Inc. BioRestorative (NASDAQ:BRTX) is a clinical-stage biotechnology company developing cell-based therapies using adult stem cells to address unmet needs in musculoskeletal and metabolic diseases. The Company's pipeline includes BRTX-100, a novel therapy targeting chronic lumbar disc disease, and ThermoStem ®, a platform focused on brown adipose (fat) biology for the treatment of obesity and metabolic disorders. The Company also operates a commercial BioCosmeceutical platform. For more information, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements. Contact: Stephen Kilmer Investor Relations Direct: (646) 274-3580 Email: skilmer@ Featured Image @ Freepik Read more investing news on to the PressReach RSS feeds:

Physicians brace for summer travel season as Alberta tops 800 measles cases
Physicians brace for summer travel season as Alberta tops 800 measles cases

CBC

time2 hours ago

  • CBC

Physicians brace for summer travel season as Alberta tops 800 measles cases

As summer approaches, Alberta's measles case counts are expected to keep climbing and some experts worry transmission will become even more widespread. With 31 new cases reported over the weekend, Alberta's total case count jumped to 809 by midday Monday. Five people are currently hospitalized due to the virus, including two patients who are in intensive care. The outbreaks began in March and while cases have been confirmed in all zones, the south, central and north zones are the hardest hit. "This is not showing signs of slowing at this point," said Caroline Colijn, a professor and Canada Research Chair of Mathematics for Evolution, Infection and Public Health at Simon Fraser University. She predicts Alberta's measles case counts will keep climbing for months. "I would expect it will continue to transmit and find pathways through our population to reach people who are not protected." Dr. Sam Wong, president of the Alberta Medical Association's section of pediatrics, is worried about what's to come. "In a few weeks' time, if the numbers keep going ... I think that we're going to hit over 1,000 [cases]. We're going to hit more measles cases in Alberta than they have in the States," said Wong. According to the U.S. Centers for Disease Control and Prevention, 1,168 cases had been confirmed in the entire country, as of June 6. "That is mind-boggling to me," Wong said. "And it speaks to the failure of the [Alberta] government to do their job when they could have done it earlier on." Summer travel At the University of Calgary, Craig Jenne will be watching the trends in the coming weeks. He's concerned summer activities, such as travel, could spark even more widespread transmission. "As we get into the next several weeks people will be starting summer vacations. We will see festivals ... Calgary Stampede is in a few weeks. We may then see community level transmission expand beyond the south zone," said Jenne, a professor in the department of microbiology, immunology and infectious diseases. Experts say a single case of measles transported into an area with low vaccination rates is akin to a spark landing in a tinder dry forest. "I think travel between and among communities with low immunization ... will allow the virus a path to get into a new, close-knit community where vaccination rates are low," said Colijn. The south zone accounts for 71.6 per cent of Alberta's total cases. A standing exposure advisory remains in effect for that part of the province due to widespread transmission. Health officials have warned official case counts are the "tip of the iceberg" in southern Alberta due to unreported and undetected cases. Dr. Paul Parks is seeing that firsthand in the Medicine Hat emergency room where he works. He, too, is bracing for further outbreaks in the province. "It's such a contagious illness," said Parks, who is also the past-president of the Alberta Medical Association. "As people are out at mass gathering events and as Stampede comes and as all these different events happen, we're going to have more and more spread." The measles virus can hang in the air for several hours after an infected person leaves a location. More than 90 per cent of people who are not immune and are exposed to the virus will end up infected, according to the Alberta government. "The other thing to think about is ... Alberta could be a source of measles introductions to other places," said Colijn. "We may see a broader geographic spread because of summer travel from Alberta more than to Alberta. That's very hard to predict." The vast majority of Alberta's cases are among unimmunized individuals, provincial data shows. Measles can lead to serious complications including pneumonia, brain inflammation, premature delivery and even death. Children under the age of five, people with weakened immune systems and pregnant individuals are at the highest risk of severe complications. The province says 64 Albertans have been hospitalized due to measles this year, as of May 31. Ten of those people have ended up in intensive care.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store